Document Detail


Haemoglobin--is more better?
MedLine Citation:
PMID:  7644107     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recombinant human erythropoietin (r-HuEPO) treatment reduces cardiac output and increases left ventricular mass: beneficial effects that might be expected to be maximized at near-normal haemoglobin values. Quality of life in dialysis patients treated with r-HuEPO has been shown to be related to haemoglobin, up to a haematocrit of 35%. The potential benefits of increasing the target haemoglobin must, however, be seen in the context of the haemodynamic changes that occur during r-HuEPO treatment, in particular, increased peripheral resistance (leading to hypertension), and possible adverse effects on the coagulation system and microcirculation. Pending further trials with a target haemoglobin of 14 g/dl or a haematocrit of 40%, a target haematocrit of 34-37% seems reasonable; it might also be appropriate to adjust the target haematocrit according to the individual's symptoms and lifestyle.
Authors:
J Walls
Related Documents :
2867837 - Effects of new inotropic agents on exercise performance.
421317 - Ventricular premature contractions: a randomized non-drug intervention trial in normal ...
14616537 - An advanced physiological controller design for a left ventricular assist device to pre...
3516187 - Afterload reduction: a comparison of captopril and nifedipine in dilated cardiomyopathy.
18228167 - History of developments in sport and exercise physiology: a. v. hill, maximal oxygen up...
3372547 - Wear, creep, and frictional heating of femoral implant articulating surfaces and the ef...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  10 Suppl 2     ISSN:  0931-0509     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  1995  
Date Detail:
Created Date:  1995-09-21     Completed Date:  1995-09-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  56-61     Citation Subset:  IM    
Affiliation:
Department of Nephrology, Leicester General Hospital, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia / therapy
Erythropoietin / pharmacology*,  therapeutic use
Hemodynamics / drug effects
Hemoglobins / analysis*
Humans
Muscles / drug effects,  metabolism
Quality of Life
Recombinant Proteins / pharmacology
Renal Dialysis
Chemical
Reg. No./Substance:
0/Hemoglobins; 0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Haemoglobin--is more better?
Next Document:  R-HuEPO hyporesponsiveness--who and why?